Second-line chemotherapy with a modified schedule of docetaxel in elderly patients with advanced-stage non-small-cell lung cancer

Clinical Lung Cancer

Volumn 7, Issue 6, 2006, Pages 401-405

  Tibaldi, Carmelo ^a   Bernardini, Haria ^a   Chella, Antonio ^b   Russo, Francesa ^a   Vasile, Enrico ^a   Malventi, Michele ^a   Falcone, Alfredo ^a,c  

^a Civil Hospital   (Italy)

^b CISANELLO HOSPITAL   (Italy)

^c UNIVERSITY OF PISA   (Italy)

Author keywords

Best supportive care; Dexamethasone; Performance status; Toxicity

Indexed keywords

DEXAMETHASONE; DOCETAXEL; GEMCITABINE; NAVELBINE; SEROTONIN 3 ANTAGONIST;

ADVANCED CANCER; AGED; ANEMIA; ARTICLE; ASTHENIA; BLEEDING; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; FUNCTIONAL ASSESSMENT; GERIATRIC CARE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MUCOSA INFLAMMATION; NAIL DISEASE; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PATIENT COMPLIANCE; SKIN TOXICITY; STATISTICAL ANALYSIS; THROMBOCYTOPENIA; TREATMENT DURATION; VOMITING;

EID: 33745893771     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2006.n.024     Document Type: Article

References (20)

1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001; 2:533-543.
2. Lee-chiong TL Jr, Matthay RA. Lung cancer in the elderly patient. Clin Chest Med 1993; 14:453-478.
3. Shepherd FA, Dancey J, Damlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18:2095-2103.
4. Fossella FV, Devore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 2000; 18:2354-2362.
5. National Cancer Institute. Cancer therapy evaluation programs (CTEP) common toxicity criteria-version 2.0. Bethesda (MD) (1999): Division of cancer treatment and diagnosis, national cancer institute. Available at: http://ctep.cancer.gov/reporting/ctc.html. Accessed January 2002.
6. Therasse P, Arbuck G, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92:205-216.
7. Kaplan E, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1993; 53:1245-1252.
8. Pfister DG, Johnson DH, Azzoli CG, et al. American society of clinical oncology treatment of unresectable non-small-cell-lung cancer guideline: update 2003. J Clin Oncol 2004; 22:330-353.
9. Fossella FV, Lee JS, Shin DM, et al. Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. J Clin Oncol 1995; 13:645-651.
10. Gandara DR, Vokes E, Green M, et al. Activity of docetaxel in platinum treated non small cell lung cancer: Results of a phase II multicenter trial. J Clin Oncol 2000; 18:131-135.
11. Alexopoulos K, Kouroussis C, Androulakis N, et al. Docetaxel and granulocyte colony-stimulating factor in patients with advanced non small cell lung cancer previously treated with platinum-based chemotherapy; a multicenter phase II trial. Cancer Chemother Pharmacol 1999; 43:257-262.
12. Gridelli C, Frontini I, Barletta E, et al. Single agent docetaxel plus granulocyte-colony stimulating factor (G-CSF) in previously treated patients with advanced non small cell lung cancer. A phase II study and review of the literature. Anticancer Res 2000; 20:1077-1084.
13. Gridelli C, Gallo C, Di Maio M, et al. A randomized clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non small cell lung cancer. The distal 01 study. Br J Cancer 2004; 91:1996-2004.
14. Camps C, Massutti B, Jimenez AM, et al. Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial. Ann Oncol 2006; 17:467-472.
15. Schuette W, Nagel S, Blankenburg T, et al. Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel. J Clin Oncol 2005; 23:8389-8395.
16. Engels FK, Verweij J. Docetaxel administration schedule: from fever to tears? A review of randomised studies. Eur J Cancer 2005; 41:1117-1126.
17. Gervais R, Ducolone A, Breton JL, et al. Phase II randomized trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC). Ann Oncol 2005; 16:90-96.
18. Le Caer H, Gimenez C, Fournel P, et al. A multicenter phase II study of docetaxel (D) or docetaxel/gemcitabine (G) weekly in advanced non-small cell lung cancer (NSCLC) in elderly and/or poor performance status (PS) patients (pts). (GFPC 0202). J Clin Oncol 2005; 23(16 suppl):657s (Abstract #7150).
19. Lilenbaum R, Rubin M, Samuel J, et al. A phase II randomized trial of docetaxel weekly or every 3 weeks in elderly and/or poor performance status (PS) patients (pts) with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2004; 23:627 (Abstract # 7057).
20. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non small cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22:1589-1597.